Pradaxa Lawsuits Consolidated in Illinois

The mounting number of Pradaxa lawsuits led to a consolidation of all the federally filed mass cases.

Allvoices, an online media outlet, reported in August 2012 that the Joint Panel on Multidistrict Litigation, a panel of federal judges, consolidated all current and future Pradaxa cases filed in federal courts to be heard by Judge David R. Herndon, the chief judge of the Southern District of Illinois. What the cases shared in common was alleged damages such as bleeding and other injuries caused by Pradaxa. In 2011, more adverse reports and deaths were reported for Pradaxa than all other monitored drugs, according to USA Today. The Food and Drug Administration (FDA) received reports of 542 deaths and 3,781 adverse effects linked to Pradaxa.

Pradaxa manufacturer Boehringer Ingelheim marketed the drug as a blood anti-clotting agent approved by the FDA to use for patients who had irregular heartbeats. The company marketed it as a safe replacement for its counterpart Coumadin, a blood thinner that required more close monitoring and a dietary regimen. Pradaxa drug sales surpassed $1 billion. However, the motivation to the rush the drug to market appears to be for reaping the profits rather than producing a safer, more effective product. A Pradaxa lawsuit lawyer is well-versed in the shortcomings, flaws and dangers of Pradaxa, and many attorneys continue to pave the way so patients can hold the pharmaceutical company accountable for their injuries.

Phillips Law Offices brings decades of experience to our legal practice and a successful track record of handling pharmaceutical liability lawsuits for drugs like Pradaxa. Take advantage of our free consultation and find out how we can help.